FiercePharma

U.S. FDA Approves Dual-Chamber Syringe for Abilify Maintena® (aripiprazole) Extended-Release Injectable Suspension for the Treatment of Schizophrenia

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck announced today that the U.S. Food and Drug Administration (FDA) ...
Monthly Prescribing Reference

New Inj Site for Abilify Maintena Approved

ABILIFY MAINTENA (aripiprazole) 300mg and 400mg ext-rel injectable suspension Lundbeck and Otsuka announced that the Food and Drug Administration (FDA) has expanded the label of Abilify Maintena ...
Business Wire

Otsuka and Lundbeck Published Study Results Showing Aripiprazole 2-Month, Ready-to-Use, Long-Acting Injectable is as Well-Tolerated, and Provides Similar Plasma Levels as ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd (Otsuka) and H. Lundbeck A/S (Lundbeck) published results from research demonstrating that an investigational ...
STAT

New long-acting injectable helps manage schizophrenia or bipolar I symptoms for two-months

According to the National Institute on Minority Health and Health Disparities (NIMHD), less than half of all Americans who have a mental disorder get proper treatment, and less than 10% of patients ...
FiercePharma

Otsuka, Lundbeck gain FDA nod for longer-acting version of schizophrenia drug Abilify

Longer-acting formulas have made the treatment of schizophrenia more convenient and reliable for patients. Now, stepping to the plate with another long-acting treatment are Otsuka and Lundbeck. On ...